Biocat and Farmaindustria sign strategic agreement to promote healthcare innovation

The National Trade Association of the Spanish-based Pharmaceutical Industry (Farmaindustria) and Biocat signed a two-year collaboration agreement, with an automatic two-year extension, establishing a new path for collaborations to transform the healthcare sector. The partnership was signed by Farmaindustria President Fina Lladós and Biocat CEO Robert Fabregat at the Biocat offices.

This agreement will allow Farmaindustria and Biocat to pool their resources and expertise to strengthen the BioRegion of Catalonia, promoting the development of new therapies and drugs, as well as establishing more efficient public-private partnership models.

The main goals of the agreement are:

1. Shoring up the BioRegion of Catalonia’s leadership in clinical research, providing research groups and academic institutions ways to connect with biopharmaceutical companies.
2. Promoting the development of advanced therapies and personalized medicine, establishing synergies in promoting the Advanced Therapies Network of Catalonia.
3. Collaborating to implement the Healthcare System Access Program (PASS).
4. Attracting, training and retaining talent in the ecosystem, promoting projects like the Jóvenes en Farma platform.
5. Working together to raise awareness of the services of both organizations, boosting their reach and maximizing their impact.

Alongside the collaboration agreements, a follow-up committee will also be created with representatives from both organizations to monitor and assess the initiatives. The committee will meet twice a year and ensure the collaboration is flexible and in line with the sector’s changing needs. 

This agreement is another step forward in making Catalonia and Spain global leaders in healthcare innovation, ensuring positive impacts for both professionals in the sector and patients, who will benefit from faster access to advanced therapies and innovative treatments.